Clinical Trial Update: Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a sirolimus, mycophenolate mofetil, and bortezomib regimen as graft-versus-host disease prophylaxis after reduced-intensity condition…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Rapamune (sirolimus)
• Velcade (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Graft-vs-Host Disease | Phase 2 | Status: TERMINATED | Results posted: 2014-10-21